C4 Therapeutics Inc (CCCC)vsMerck & Company Inc (MRK)
CCCC
C4 Therapeutics Inc
$3.51
+3.24%
HEALTHCARE · Cap: $431.82M
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 189885% more annual revenue ($66.57B vs $35.04M). MRK leads profitability with a 4.8% profit margin vs -289.4%. MRK earns a higher WallStSmart Score of 36/100 (F).
CCCC
Avoid28
out of 100
Grade: F
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.8%
Fair Value
$5.86
Current Price
$3.51
$2.35 discount
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
2.8% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : CCCC
The strongest argument for CCCC centers on Debt/Equity, Price/Book.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : CCCC
The primary concerns for CCCC are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
CCCC profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
CCCC carries more volatility with a beta of 2.94 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 28/100). CCCC offers better value entry with a 68.8% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
C4 Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
C4 Therapeutics, Inc., a biopharmaceutical company, develops new therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company is headquartered in Watertown, Massachusetts.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?